Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Systemic Nocardiosis Mimicking Disease Flare-up after Discontinuation of Gefitinib in a Patient with EGFR-Mutant Lung Cancer.

Literature DB >> 25580145

Systemic Nocardiosis Mimicking Disease Flare-up after Discontinuation of Gefitinib in a Patient with EGFR-Mutant Lung Cancer.

Mihong Choi¹, Youngjoo Lee¹, Sang Hyun Hwang², Jin Soo Lee¹.

Abstract

Disease flare-up after discontinuing epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been considered as a critical issue in lung cancer patients who have experienced radiologic progression after showing initial durable response. This is a case of systemic nocardiosis that occurred after chronic steroid use for radionecrosis from stereotactic radiosurgery. It was initially thought as a disease flare-up after stopping EGFR-TKI.

Entities: Chemical Disease Gene Species

Keywords: Carcinoma, Non-Small-Cell Lung; EGFR Tyrosine Kinase Inhibitor 324674; Nocardia Infections; Radiosurgery

Year: 2014 PMID： 25580145 PMCID： PMC4286786 DOI： 10.4046/trd.2014.77.6.271

Source DB: PubMed Journal: Tuberc Respir Dis (Seoul) ISSN： 1738-3536

6 in total

Review 1. Nocardiosis: review of clinical and laboratory experience.

Authors: Michael A Saubolle; Den Sussland
Journal: J Clin Microbiol Date: 2003-10 Impact factor: 5.948

2. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

Authors: Jamie E Chaft; Geoffrey R Oxnard; Camelia S Sima; Mark G Kris; Vincent A Miller; Gregory J Riely
Journal: Clin Cancer Res Date: 2011-08-19 Impact factor: 12.531

3. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors: Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal: N Engl J Med Date: 2004-04-29 Impact factor: 91.245

1 in total

1. Serum neuron specific enolase levels correlate with patient prognosis for advanced lung cancer.

Authors: Feng Xue; Lin Zhu; Liyan Wang; Quan Wang
Journal: Int J Clin Exp Med Date: 2015-06-15

1 in total

Systemic Nocardiosis Mimicking Disease Flare-up after Discontinuation of Gefitinib in a Patient with EGFR-Mutant Lung Cancer.

Review 1. Nocardiosis: review of clinical and laboratory experience.

2. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

3. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

4. The results of resection after stereotactic radiosurgery for brain metastases.

5. Survival and pattern of failure in brain metastasis treated with stereotactic gamma knife radiosurgery.

Review 6. Nocardiosis: updated clinical review and experience at a tertiary center.

1. Serum neuron specific enolase levels correlate with patient prognosis for advanced lung cancer.